Emergent BioSolutions | EBS - Nettoeinkommen





Nettoeinkommen Veränderung Datum
Acadia Pharmaceuticals USD 53.52M 22.02M 2026-09
Akebia Therapeutics USD -12.24M 12.78M 2025-12
ALKERMES USD 16.29M 15.79M 2026-09
Alnylam Pharmaceuticals USD 2.17B 2B 2026-09
Amarin USD -1.22M 6.51M 2025-12
ANI Pharmaceuticals USD 35.15M 10.44M 2026-09
BioMarin Pharmaceutical USD -122.83M 167.59M 2026-09
Coherus Biosciences USD -37.64M 2.11M 2025-12
Emergent BioSolutions USD -261.3M 78.3M 2023-06
Exelixis USD 218.1M 6.04M 2026-09
Glaxosmithkline GBP 1.54B 194M 2026-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -114.65M 21.65M 2026-06
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
Lexicon Pharmaceuticals USD -15.53M 2.76M 2025-12
Lonza CHF 426M 119M 2025-06
Merck USD 5.07B 6.4B 2026-09
Moderna USD 162M 944M 2026-09
Myriad Genetics USD -7.9M 19.5M 2025-12
Nektar Therapeutics USD -44.9M 8.82M 2026-03
Neurocrine Biosciences USD 144.4M 53.5M 2026-06
Pacira USD 325.3M 320.65M 2026-09
Pfizer USD 3.24B 3.49B 2026-09
PTC Therapeutics USD 83.5M 86.3M 2026-06
Sanofi EUR 3.02B 2.68B 2026-09
Sarepta Therapeutics USD -28.46M 23.57M 2026-09
United Therapeutics USD 258.6M 74.4M 2026-09
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12